ICOSLG — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1799816	0.56	13/20
SCHEMBL13315672	0.56	13/20
SCHEMBL1798662	0.55	13/20
SCHEMBL12619377	0.55	13/20
SCHEMBL1800039	0.53	13/20
SCHEMBL1800076	0.53	13/20
SCHEMBL12619404	0.53	13/20
SCHEMBL12619412	0.53	13/20
SCHEMBL13315659	0.53	13/20
SCHEMBL1797470	0.52	13/20
SCHEMBL1800498	0.52	13/20
SCHEMBL12619419	0.52	13/20
SCHEMBL12653018	0.52	13/20
SCHEMBL13376947	0.74	12/20
SCHEMBL3994817	0.63	12/20
SCHEMBL13847917	0.57	12/20
SCHEMBL12653318	0.56	12/20
SCHEMBL12619407	0.55	12/20
SCHEMBL1800497	0.52	12/20
SCHEMBL1796475	1.00	11/20

Clinical trials — most relevant to ICOSLG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria	PHASE4	RECRUITING
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)	PHASE3	COMPLETED
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma	PHASE3	COMPLETED
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma	PHASE3	COMPLETED
Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma	PHASE1/PHASE2	NOT_YET_RECRUITING
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab	PHASE2	NOT_YET_RECRUITING
A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer	PHASE2	NOT_YET_RECRUITING
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors	PHASE2	COMPLETED
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .	PHASE2	NOT_YET_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab in Muscle-invasive Bladder Cancer	PHASE2	ACTIVE_NOT_RECRUITING
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)	PHASE2	ACTIVE_NOT_RECRUITING
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation	PHASE2	NOT_YET_RECRUITING
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.	PHASE2	RECRUITING
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy	PHASE2	COMPLETED
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)	PHASE2	ACTIVE_NOT_RECRUITING
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers	PHASE2	ACTIVE_NOT_RECRUITING
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)	PHASE2	COMPLETED
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer	PHASE2	RECRUITING
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer	PHASE2	COMPLETED
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors	PHASE1	COMPLETED
Study of AK119 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment	nan	NOT_YET_RECRUITING
Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix	nan	ENROLLING_BY_INVITATION
To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ICOSLG binder may also engage these)

Protein	Name	Similarity
PDCD1LG2	Programmed cell death 1 ligand 2	0.981	landscape →
P33681	—	0.980	P33681 →
P42070	—	0.979	P42070 →
Q9JHJ8	—	0.974	Q9JHJ8 →
Q9WUL5	—	0.973	Q9WUL5 →
P20917	—	0.970	P20917 →
P15151	—	0.970	P15151 →
MAG	Myelin-associated glycoprotein	0.968	landscape →
P32506	—	0.968	P32506 →
P01896	—	0.967	P01896 →
Q9EP73	—	0.965	Q9EP73 →
P31994	—	0.965	P31994 →
Q8N0Z9	—	0.964	Q8N0Z9 →
Q8R007	—	0.964	Q8R007 →
P16410	—	0.963	P16410 →
Q9MYX7	—	0.963	Q9MYX7 →
Q75VT8	—	0.963	Q75VT8 →
O95727	—	0.962	O95727 →
P38484	—	0.961	P38484 →
P31995	—	0.961	P31995 →
Q9UM44	—	0.961	Q9UM44 →
P07722	—	0.961	P07722 →
P09793	—	0.960	P09793 →
P01831	—	0.960	P01831 →
Q5NKV1	—	0.960	Q5NKV1 →
Q9R069	—	0.960	Q9R069 →
CD274	Programmed cell death 1 ligand 1	0.960	landscape →
Q9ES58	—	0.960	Q9ES58 →
Q8SPV8	—	0.960	Q8SPV8 →
Q29612	—	0.959	Q29612 →